Skip to content
PubMed This is a summary of 48 peer-reviewed journal articles Updated
Metabolic medicine · N-acetylglutamate synthase deficiency

Hyperammonemia due to N-acetylglutamate synthase deficiency: A Patient Guide

At a Glance

N-acetylglutamate synthase (NAGS) deficiency causes ammonia to build up because the liver cannot start the urea cycle normally. Carglumic acid replaces the missing signal, but daily treatment, dietitian guidance, and an illness plan are essential.

Receiving a diagnosis of N-acetylglutamate synthase (NAGS) deficiency means entering a world of medical terminology and rare genetics, but at its heart, it is a condition defined by a single missing signal. This condition belongs to a group of disorders called urea cycle disorders, which affect how your body handles the natural breakdown of protein. Every time you eat protein or your body uses its own muscle for energy, it creates nitrogen waste.

Normally, protein breakdown generates ammonia-containing nitrogen, and the urea cycle in the liver converts that ammonia into urea, which is safely excreted in urine [1][2]. In NAGS deficiency, the body lacks the specific enzyme (a functional protein) needed to create the “key” that starts this entire cycle.

Because the cycle cannot start, this block prevents the conversion to urea, leading to a buildup of ammonia, a substance that is highly toxic to the brain when elevated. This buildup, known as hyperammonemia, is the primary challenge of the condition and can lead to serious neurological symptoms. While this sounds daunting, NAGS deficiency is unique among urea cycle disorders because of how directly it can be treated. Because the problem is a missing “key” (a molecule called N-acetylglutamate), medical science has developed a way to provide a replacement that functions just like the real thing [3][4].

The cornerstone of living with this condition is a medication called carglumic acid. This treatment acts as a stable substitute for the missing signal in your liver, effectively “unlocking” the urea cycle. When taken consistently, this medication can often normalize ammonia levels and keep them stable. One of the most encouraging aspects of successful treatment is that some patients may be able to eat a near-normal or even completely normal amount of dietary protein, although this must always be guided and monitored by a metabolic dietitian [5][6].

However, the effectiveness of this treatment depends entirely on consistency. The body is constantly processing nitrogen, so the urea cycle must be kept “active” at all times. Access to carglumic acid must never be interrupted; even a short gap in treatment can leave the body vulnerable to a rapid rise in ammonia. Carglumic acid treats the metabolic block, but it does not cure the underlying genetic deficiency [6].

In addition to daily medication, staying healthy means being prepared for times of physical stress, such as during a fever, a stomach bug, or surgery. These “catabolic” states can cause the body to break down its own protein, putting extra pressure on the urea cycle. By working closely with a specialized metabolic team and following a clear emergency protocol, you can protect your brain and your health. For those diagnosed early and treated consistently without prior brain injury, the long-term outlook is encouraging, often allowing for healthy development and a full range of life activities [7][8].

Common questions in this guide

What is N-acetylglutamate synthase deficiency?
It is a genetic urea cycle disorder in which the liver lacks the enzyme needed to make N-acetylglutamate, the signal that starts ammonia disposal. As a result, ammonia can build up in the blood and harm the brain if it is not treated.
How is NAGS deficiency confirmed?
A metabolic team may use molecular genetic testing to confirm the diagnosis, while some treatment decisions may initially be guided by the clinical response to carglumic acid. Ask your care team whether the diagnosis is genetically confirmed and what evidence supports it.
How does carglumic acid treat NAGS deficiency?
Carglumic acid acts as a stable replacement for the missing N-acetylglutamate signal, helping unlock the liver’s urea cycle. It can normalize ammonia levels, but it manages rather than cures the underlying genetic deficiency.
Can someone with NAGS deficiency eat a normal amount of protein?
Some patients may eventually tolerate near-normal or normal dietary protein when ammonia is controlled. Protein changes must be planned and monitored by a metabolic dietitian because needs vary.
Why is it important not to interrupt carglumic acid treatment?
The body is constantly producing nitrogen waste, so the urea cycle needs ongoing support. Even a short gap in treatment can allow ammonia to rise quickly, so discuss backup supplies and missed-dose instructions with your metabolic team.
What should happen during a fever, stomach illness, or surgery?
These physical stresses can cause the body to break down its own protein, increasing the risk of high ammonia. Follow your personalized emergency protocol and contact your specialized metabolic team promptly for guidance.
What is the long-term outlook for NAGS deficiency?
For people diagnosed early and treated consistently without previous brain injury, the outlook is often encouraging. Treatment may support healthy development and participation in a full range of life activities, with ongoing monitoring by the care team.

Get notified when new evidence is published on Hyperammonemia due to N-acetylglutamate synthase deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Partial N-acetyl glutamate synthase deficiency presenting as postpartum hyperammonemia: Diagnosis and subsequent pregnancy management.

    Abou Haidar L, Pachnis P, Gotway GK, et al.

    JIMD reports 2023; (64(6)):403-409 doi:10.1002/jmd2.12388.

    PMID: 37927481
  2. 2

    Noncoding sequence variants define a novel regulatory element in the first intron of the N-acetylglutamate synthase gene.

    Häberle J, Moore MB, Haskins N, et al.

    Human mutation 2021; (42(12)):1624-1636 doi:10.1002/humu.24281.

    PMID: 34510628
  3. 3

    The N-Acetylglutamate Synthase Family: Structures, Function and Mechanisms.

    Shi D, Allewell NM, Tuchman M

    International journal of molecular sciences 2015; (16(6)):13004-22 doi:10.3390/ijms160613004.

    PMID: 26068232
  4. 4

    N-acetylglutamate synthase deficiency: Novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra.

    Al Kaabi EH, El-Hattab AW

    Molecular genetics and metabolism reports 2016; (8()):94-8 doi:10.1016/j.ymgmr.2016.08.004.

    PMID: 27570737
  5. 5

    N-Acetylglutamate Synthase Deficiency Due to a Recurrent Sequence Variant in the N-acetylglutamate Synthase Enhancer Region.

    Williams M, Burlina A, Rubert L, et al.

    Scientific reports 2018; (8(1)):15436 doi:10.1038/s41598-018-33457-0.

    PMID: 30337552
  6. 6

    The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency.

    Singh RH, Bourdages MH, Kurtz A, et al.

    Orphanet journal of rare diseases 2024; (19(1)):168 doi:10.1186/s13023-024-03167-0.

    PMID: 38637895
  7. 7

    Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature.

    Kenneson A, Singh RH

    Orphanet journal of rare diseases 2020; (15(1)):279 doi:10.1186/s13023-020-01560-z.

    PMID: 33036647
  8. 8

    Early care of N-acetyl glutamate synthase (NAGS) deficiency in three infants from an inbred family.

    Peoc'h K, Damaj L, Pelletier R, et al.

    Molecular genetics and metabolism reports 2020; (22()):100558 doi:10.1016/j.ymgmr.2019.100558.

    PMID: 32021803

This page is for informational purposes only and does not constitute medical advice about NAGS deficiency or hyperammonemia. Your metabolic team should guide carglumic acid use, protein intake, medication access, and emergency care.